FDA Updates Testosterone Labeling for Blood Pressure and Cardiovascular Risks

The US Food and Drug Administration (FDA) recently issued class-wide labeling changes for testosterone products, recommending that labels include a warning about increased blood pressure and remove language related to elevated risk of adverse cardiovascular outcomes.

Authors

Publication Details

Journal
JAMA
Published
2025-04-04
DOI
https://doi.org/10.1001/jama.2025.3240
Citations
3
Primary Topic
Hormonal and reproductive studies
Type
article
Field-Weighted Citation Impact
3.88
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

FDA Updates Testosterone Labeling for Blood Pressure and Cardiovascular Risks

Samantha Anderer
3 citations
JAMA
Hormonal and reproductive studies
3.88
article

FDA Updates Testosterone Labeling for Blood Pressure and Cardiovascular Risks

Samantha Anderer
article en
3 citations

Abstract

The US Food and Drug Administration (FDA) recently issued class-wide labeling changes for testosterone products, recommending that labels include a warning about increased blood pressure and remove language related to elevated risk of adverse cardiovascular outcomes.

JAMAVol. 333(17)
Good health and well-being
Openalex Percentile: Top 7%
Hormonal and reproductive studies
3.88
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

FDA Updates Testosterone Labeling for Blood Pressure and Cardiovascular Risks — Samantha Anderer · JAMA (2025) | TGRS Research Map | TGRS